Wantstats
Company ProfilePremium

Sinclair Pharma

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Sinclair Pharma - Healthcare showcase

Year Founded & Workforce

1971

1,000 Employees

Industry

Healthcare

Services

Dermal Filler
S

Sinclair Pharma Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sinclair Pharma Overview

Company Headquarters: London, UK

Founded: 1971

Workforce: 1,000

Company Working: Sinclair Pharma is a global healthcare company engaged in the development, manufacture, and distribution of pharmaceutical products. Other medical offerings of the company include aesthetics and cosmetic products. It has a portfolio of differentiated complementary aesthetics technologies with a focus on collagen stimulation. The company constitutes a huge network of international distributors throughout the world. Sinclair Pharma operates as a subsidiary of Huadong Medicine Co., Ltd.(China). The company has a strong presence in Europe, as well as the US, Brazil, and South Korea

Strategy

Sinclair Pharma aims to focus on major aesthetic markets such as the US, the UK, and Brazil by providing quality products and generating maximum revenue from these markets. Moreover, it also focuses on internal development capabilities, which would be concentrated on utilizing both the current portfolio and new development potential. The company plans to collaborate with different physicians and clinics to create awareness about its products in the market.

Company Snapshot

$5,430.4M

Revenue

1,000

Employees

1971

Founded

London, UK

Headquarters

SWOT Analysis

Strengths

  • Strong distribution network
  • Collaborations with physicians and clinics
  • The company is present in all major markets
  • Quality products
  • Skilled workforce

Weaknesses

  • Limited geographic presence
  • Depended on the aesthetics segment for revenue generation

Opportunities

  • Strategic collaborations and partnerships
  • Geographical expansion through collaborations and mergers and acquisitions
  • New product launches

Threats

  • Stringent government regulations
  • Tough market competition
  • Extensive regulations

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
August 2015PartnershipSinclair Pharma partnered with John Bannon Ltd to supply its aesthetic range in Ireland.
–AcquisitionSinclair Pharma was acquired by Huadong Medicine Co., Ltd. With this, the company expanded its aesthetic products portfolio.
–Product LaunchSinclair Pharma launched Silhouette InstaLift in the market. It offers dual benefits of an instant facelift and volumization for both men and women.
–AgreementSinclair Pharma and Thermigen entered into a strategic distribution agreement for Silhouette InstaLift in the US.
May 2021Product LaunchSinclair Pharma (UK) launched the facial filler MaiLi, which contains hyaluronic acid (HA). Premium hyaluronic acid (HA) is used in the newest generation of dermal fillers, MaiLi, to deliver results that are long-lasting and seem natural. While keeping your natural expression and movement, this strong dermal filler provides your skin extra suppleness, volume, and longevity
March 2020AgreementSinclair Pharma (UK) announced the license agreement for MaiLi, a premium innovative facial hyaluronic acid (HA) range with lidocaine. MaiLi technology has been developed by Kylane Laboratories, a Swiss R&D medtech company driven by an expert team with an extensive track record in the HA field. Thus, with this move, Sinclair Pharma aims to expand its foothold in the dermal fillers market.
February 2020AgreementSinclair Pharma (UK) announced the completion of a transaction in which Swiss-based Galderma Laboratories, L.P. acquired the European distribution rights to Sculptra (poly-I-Iactic acid).

Product Offering

  • Sinclair Pharma
    • Dermal Filler

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 5,430.4 Mn in 2019 to USD 5,422.8 Mn in 2021.
Sinclair Pharma — By Business Segment
Series (USD Mn)201920202021
Sales5,430.45,160.45,422.8
R&D Expenditure153.5141.9686.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →